ACADIA Pharmaceuticals Inc. ACAD
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 53.52M | 31.50M | 3.64M | 273.57M | 71.78M |
| Total Depreciation and Amortization | 3.65M | 3.16M | 2.99M | 2.92M | 2.95M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.88M | 26.66M | 14.15M | -237.31M | 12.08M |
| Change in Net Operating Assets | -77.55M | 39.46M | 13.20M | -87.91M | -12.52M |
| Cash from Operations | 11.50M | 100.78M | 33.98M | -48.73M | 74.29M |
| Capital Expenditure | -1.24M | -5.09M | -5.21M | -4.01M | -388.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -84.91M | -3.44M | 71.49M | -51.86M | -78.96M |
| Cash from Investing | -86.15M | -8.53M | 66.28M | -55.87M | -79.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.87M | 10.49M | 4.23M | 22.67M | 9.42M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11.87M | 10.49M | 4.23M | 22.67M | 9.42M |
| Foreign Exchange rate Adjustments | 159.00K | 27.00K | 25.00K | 7.00K | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.62M | 102.77M | 104.52M | -81.93M | 4.36M |